COPENHAGEN, Denmark — Alisertib monotherapy may be effective in certain patients with clinical or pathologically defined neuroendocrine prostate cancer, according to phase 2 study results presented at the European Society for Medical Oncology Congress.
SANTA MONICA, CA — The Prostate Cancer Foundation (PCF) announces 5 new Movember Foundation-PCF Challenge Awards to advance new treatments and cures for metastatic, lethal prostate
In order to benefit from the latest advances in precision medicine, Himisha Beltran, M.D., has to subject her prostate cancer patients to invasive biopsies that can be painful, expensive, difficult to perform, and not always feasible.
